Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by KandiBirdBoyon Apr 27, 2021 7:26am
60 Views
Post# 33072798

FSD Pharma VOTE GOLD

FSD Pharma VOTE GOLD
Dr. Raza Bokhari and his collaborating directors have spent shareholder money in these attempts to entrench themselves and prevent shareholders from having a say in the leadership of the company:
 

 Failure to Achieve Stated Goals:       o h     n the o      ent e se e  e
goals. To date, Dr. Bokhari and his collaborating directors have failed to achieve any of
these objectives: (i) while the Company’s Phase 2 clinical trial was approved in September 2020, to date the Company has announced the enrollment of only one patient, out of an "expecte " 352 p t ents w thout p o  ng spec cs on n fu the en o ment ( ) h s been unable to dispose of the Cobourg Property, and (iii) has failed to identify any appropriate strategic acquisition opportunities, instead attempting (and failing) to
execute transactions in unrelated industries and without adequate diligence.
 
 The Shareholder Meeting: The company has not held a shareholder meeting since 2019, yet Dr. Bokhari and his collaborating directors used company funds to delay holding a
meeting for as long as possible and have taken other actions to interfere with the democratic right of shareholders to determine who will serve as directors.
 
 The Court Order: Dr. Raza Bokhari and his collaborating directors attempted to enter into a transaction that would have irreparably harmed the company, resulting in a court order
preventing them from undertaking the transaction or taking any other actions outside the ordinary course of business prior to the May 14, 2021 shareholder meeting (the “Meeting”).


 Dilution: In just two months, Dr. Raza Bokhari and his collaborating directors have increased the number of outstanding Class B Shares by
a staggering 88% while the share price was close to its all-time lows. Issuing this large number of shares has further depressed the share price.
 
 Share Grants: Dr. Raza Bokhari and his collaborating directors granted themselves excessive compensation for services not yet
rendered worth approximately $6.7 million, comprised of cash and/
or Class B Shares and such shares became subject to a court order prohibiting them from being voted at the Meeting.
 
 Lack of Transparency: Repeated failures to disclose material information to shareholders, such as the court order and the resignation of the newly-
hired CEO of FSD BioSciences, Inc.
 
 Expenses: The collaborating directors approved over US $1.4 millionof Dr. Raza Bokhari’s expenses in 2020, with little transparency or explanation
<< Previous
Bullboard Posts
Next >>